Endoscopy Devices Market by Endoscope Type (Capsule Endoscopes, Flexible Endoscopes, Rigid Endoscopes), Application (Arthroscopy, Gastrointestinal Endoscopy, Laparoscopy), Usage Type, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Endoscopy Devices Market was valued at USD 47.14 billion in 2024 and is projected to grow to USD 50.61 billion in 2025, with a CAGR of 7.40%, reaching USD 83.49 billion by 2032.
Strategic overview of the endoscopy devices landscape emphasizing clinical, technological, regulatory and commercial forces shaping near-term industry priorities
The endoscopy devices sector stands at the intersection of sustained clinical demand and rapid technological innovation, where improvements in imaging, device ergonomics, and procedural integration continue to redefine standards of care. Minimally invasive approaches remain central to clinical pathways across multiple specialties, and practitioners increasingly expect instruments that deliver improved visualization, streamlined workflows, and reliable infection-control profiles. As a result, manufacturers and health systems must align product development, clinical validation, and service models to meet evolving expectations for safety, efficiency, and patient experience.
Moreover, the landscape is shaped by converging trends that include the adoption of single-use technologies, tighter infectious-disease protocols, and the rising role of digital platforms for image analysis and procedure planning. In turn, procurement and clinical leaders are balancing capital constraints with operational imperatives, assessing trade-offs between reusable capital equipment and disposables that reduce reprocessing burden. Consequently, stakeholders who anticipate regulatory shifts, invest in interoperability, and cultivate clinical evidence will secure meaningful competitive advantages in an environment where clinical value and operational resilience increasingly determine adoption.
Critical transformative shifts redefining endoscopy device development and delivery including digital imaging, robotics, disposables, and integrated care pathways impacting stakeholders
Recent transformative shifts have accelerated a redefinition of product roadmaps and commercial models in the endoscopy field, driven by advances in imaging, automation, and infection control. High-resolution optics and complementary digital tools now support enhanced diagnostic accuracy, while embedded analytics and connectivity enable new service offerings and remote clinical support. As a result, vendors are moving beyond discrete hardware sales toward integrated solutions that bundle devices with software, consumables, and clinical decision support.
At the same time, procedural robotics and articulation technologies are expanding the envelope of what is feasible in minimally invasive interventions. These innovations are not merely incremental; they change skill requirements, enable novel access strategies, and create opportunities for cross-disciplinary procedural platforms. Furthermore, the pandemic-era emphasis on single-use devices has reshaped procurement discussions by elevating infection risk and lifecycle cost alongside upfront capital considerations. Consequently, stakeholders must adapt to a landscape where product differentiation increasingly depends on ecosystem partnerships, data-enabled services, and demonstrable improvements in clinical workflows.
Projected cumulative operational and strategic consequences of United States tariffs implemented in 2025 on endoscopy device manufacturers, supply chains, and procurement dynamics
The tariff measures enacted in the United States during 2025 reshaped cost structures and sourcing strategies across the endoscopy device supply chain, prompting manufacturers and distributors to reassess production footprints and procurement channels. Immediately following tariff implementation, many suppliers evaluated nearshoring, alternative component sourcing, and supplier diversification to mitigate exposure to increased import duties. These adaptive behaviors affected lead times, inventory policies, and the relative competitiveness of products dependent on cross-border manufacturing.
In practical terms, health systems and purchasing organizations experienced upward pressure on landed costs for imported instrumentation and certain precision components, which in turn influenced purchasing cadence and contract negotiations. Meanwhile, manufacturers with established domestic assembly capabilities gained negotiating leverage and resilience, whereas smaller suppliers faced heightened margin pressure unless they passed costs through or restructured operations. Over time, these developments accelerated strategic decisions around vertical integration, supplier consolidation, and targeted product redesign to minimize tariff-sensitive inputs. Importantly, regulatory and procurement frameworks responded in kind, with payers and contracting groups increasingly scrutinizing total cost of ownership and supply continuity as part of capital procurement deliberations.
Actionable insights drawn from a granular segmentation of endoscope types, clinical applications, usage models, end users, and distribution pathways to guide product strategy
A granular segmentation view reveals distinct demand patterns that inform product development and go-to-market strategies across endoscope types, clinical applications, usage models, end users, and distribution pathways. Endoscope type differentiation among capsule, flexible, and rigid devices drives discrete design priorities: capsule systems emphasize miniaturization, battery life, and data analytics; flexible endoscopes prioritize articulation, channel compatibility, and imaging fidelity for a broad set of diagnostic and interventional procedures; rigid endoscopes continue to serve niche surgical applications where optical clarity and mechanical robustness are paramount.
Application segmentation spans arthroscopy, gastrointestinal endoscopy, laparoscopy, and urological endoscopy, each with its own procedural ecosystem. Within arthroscopy, hip, knee, and shoulder procedures present varying demands for access, optics, and instrumentation. Gastrointestinal practice areas such as colonoscopy, endoscopic ultrasound, ERCP, and gastroscopy require diverse channel configurations and therapeutic compatibility. Laparoscopy subdivides into general, gynecological, and pediatric use cases with different instrument profiles and ergonomic needs, while urological procedures like cystolithotripsy, cystoscopy, and ureteroscopy impose constraints on scope diameter, irrigation, and accessory compatibility.
Usage type presents a strategic inflection: reusable endoscopes remain attractive for high-volume, high-cost procedures where amortization makes sense, whereas single-use endoscopes respond to infection control imperatives, reprocessing labor constraints, and flexible supply needs. End user segmentation-Ambulatory Surgery Centers, hospitals, and specialty clinics-affects purchasing power, procedural mix, and the appetite for capital expenditure versus consumable-driven models. Finally, distribution channel dynamics between direct sales and distributor sales shape commercial reach, contract structures, and post-market support expectations. Taken together, these segmentation dimensions inform prioritization of R&D investment, clinical evidence generation, and tailored commercial approaches so that solutions align with distinct workflow realities and procurement behaviors.
Comparative regional intelligence across core geographies highlighting demand drivers, regulatory environments, reimbursement trends, and infrastructure readiness for endoscopy devices
Regional dynamics exert strong influence on technology adoption curves, regulatory timelines, and reimbursement mechanisms across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, purchasing behavior is driven by complex interactions among private payers, public hospitals, and ambulatory centers where capital access and value-based purchasing frameworks shape demand for devices that demonstrate procedural efficiency and patient throughput gains. Regulatory pathways in this region emphasize clinical evidence and post-market surveillance, which impacts time-to-adoption for new platform technologies.
In Europe, Middle East & Africa, heterogeneous regulatory regimes and varied healthcare infrastructure lead to differentiated adoption patterns; advanced healthcare systems in some European markets prioritize interoperability and bundled procurement, while other geographies within the region contend with constrained budgets and fragmented distribution networks. Consequently, vendors pursuing broad regional coverage must localize strategies, engage early with reimbursement bodies, and establish robust service channels. In the Asia-Pacific region, rapid hospital expansion, a growing middle class demanding minimally invasive care, and active local manufacturing hubs combine to create both opportunity and competitive intensity. Manufacturers benefit from regional partnerships, cost-optimized production, and clinical collaborations to accelerate penetration. Across all regions, stakeholders must align evidence generation, pricing strategy, and service models with local policy environments and infrastructure readiness.
Competitive intelligence on leading and emerging endoscopy device companies focusing on innovation pipelines, strategic partnerships, M&A signals, and operational resilience
Competitive dynamics among market participants center on differentiated innovation, clinical partnerships, and supply chain resilience. Leading devicemakers continue to invest in optics, miniaturization, and software-enabled capabilities to protect installed bases and create stickier revenue streams through consumables and services. At the same time, smaller and more agile entrants often focus on surgical niches, single-use concepts, or disruptive ergonomics, forcing legacy providers to accelerate product refresh cycles or pursue strategic alliances.
Strategic partnerships, co-development agreements with clinical centers, and targeted acquisitions have emerged as common playbooks to fill portfolio gaps and accelerate market access. Companies that demonstrate cross-functional excellence-combining rigorous clinical validation, field service networks, and clear total-cost considerations-tend to capture the attention of large health systems. Meanwhile, operational resilience, particularly in sourcing critical optics and electronics, remains a differentiator. Firms that diversify supplier bases, invest in redundancy, and maintain transparent supply chain communications with buyers reduce procurement friction and secure longer-term contracts. Ultimately, sustained competitive advantage will accrue to organizations that align product innovation with scalable commercial models and proactive regulatory engagement.
High-impact actionable recommendations for industry leaders to accelerate adoption, optimize supply chains, and align commercial models with evolving clinical and regulatory realities
Industry leaders should adopt a multi-dimensional strategy that balances immediate operational resiliency with long-term platform building. First, prioritize clinical evidence programs that demonstrate improvements in procedural outcomes and workflow efficiency, because payers and providers increasingly require objective data to justify adoption and reimbursement. Second, optimize supply chains by diversifying suppliers of critical components and evaluating regional assembly options to reduce exposure to tariff and logistics volatility.
Third, align commercial models with end-user economics by offering flexible pricing, outcome-based contracting where feasible, and bundled service agreements that address both capital and consumable cost centers. Fourth, accelerate digital enablement by integrating connectivity and analytics to support remote service, predictive maintenance, and enhanced clinical decision support. Fifth, pursue targeted partnerships and selective acquisitions to fill capability gaps rapidly, particularly in software, advanced imaging, and single-use consumables. Finally, invest in post-market support infrastructure and training programs to reduce adoption friction and enhance clinician confidence. Together, these actions will enable companies to respond to short-term market disruptions while building durable differentiation in an increasingly outcome-focused environment.
Transparent research methodology describing data sources, analytical frameworks, validation processes, and limitations used to synthesize the executive-level insights presented
The analysis draws on a mixed-methods research approach combining primary qualitative interviews with clinical and commercial stakeholders, synthesis of public regulatory documentation, and cross-industry benchmarking to validate thematic findings. Primary engagements included clinicians across specialties, procurement leaders, and senior operations managers who provided firsthand perspectives on procedural workflows, reprocessing practices, and procurement decision criteria. Publicly available regulatory filings and guidance documents were reviewed to contextualize market access timelines and post-market obligations.
Analytical frameworks emphasized triangulation: qualitative insights informed hypothesis generation, which was then tested against documented regulatory requirements and known commercial behaviors. Validation steps included cross-referencing supplier announcements, clinical study abstracts, and third-party logistics reports to corroborate supply chain narratives. Limitations of the methodology include reliance on available public documentation for some corporate and regulatory developments, and representativeness constraints inherent to qualitative sampling. Nevertheless, the approach prioritized high-relevance stakeholders and multiple validation layers to ensure that conclusions reflect operational realities and strategic imperatives facing manufacturers and health system purchasers.
Concise synthesis of strategic implications for stakeholders summarizing priorities, risk factors, and value levers in the evolving endoscopy device ecosystem
In closing, the endoscopy devices ecosystem is navigating a period of meaningful change where technological innovation and supply chain realities intersect with shifting clinical expectations. Stakeholders that integrate robust clinical evidence, resilient sourcing strategies, and commercially adaptable models will outperform in environments where cost containment and quality outcomes are simultaneously prioritized. Moreover, the ongoing evolution toward connected devices and data-enabled services creates new monetization pathways, but also requires disciplined regulatory engagement and clinician-centered design.
Ultimately, the imperative for manufacturers and health systems alike is to move from product-centric to outcome-centric thinking, aligning development roadmaps and procurement decisions with demonstrable clinical advantage and operational feasibility. By doing so, organizations will not only respond to immediate market pressures but also lay the groundwork for sustainable growth in a healthcare context that increasingly values safety, efficiency, and measurable patient benefit.
Please Note: PDF & Excel + Online Access - 1 Year
Strategic overview of the endoscopy devices landscape emphasizing clinical, technological, regulatory and commercial forces shaping near-term industry priorities
The endoscopy devices sector stands at the intersection of sustained clinical demand and rapid technological innovation, where improvements in imaging, device ergonomics, and procedural integration continue to redefine standards of care. Minimally invasive approaches remain central to clinical pathways across multiple specialties, and practitioners increasingly expect instruments that deliver improved visualization, streamlined workflows, and reliable infection-control profiles. As a result, manufacturers and health systems must align product development, clinical validation, and service models to meet evolving expectations for safety, efficiency, and patient experience.
Moreover, the landscape is shaped by converging trends that include the adoption of single-use technologies, tighter infectious-disease protocols, and the rising role of digital platforms for image analysis and procedure planning. In turn, procurement and clinical leaders are balancing capital constraints with operational imperatives, assessing trade-offs between reusable capital equipment and disposables that reduce reprocessing burden. Consequently, stakeholders who anticipate regulatory shifts, invest in interoperability, and cultivate clinical evidence will secure meaningful competitive advantages in an environment where clinical value and operational resilience increasingly determine adoption.
Critical transformative shifts redefining endoscopy device development and delivery including digital imaging, robotics, disposables, and integrated care pathways impacting stakeholders
Recent transformative shifts have accelerated a redefinition of product roadmaps and commercial models in the endoscopy field, driven by advances in imaging, automation, and infection control. High-resolution optics and complementary digital tools now support enhanced diagnostic accuracy, while embedded analytics and connectivity enable new service offerings and remote clinical support. As a result, vendors are moving beyond discrete hardware sales toward integrated solutions that bundle devices with software, consumables, and clinical decision support.
At the same time, procedural robotics and articulation technologies are expanding the envelope of what is feasible in minimally invasive interventions. These innovations are not merely incremental; they change skill requirements, enable novel access strategies, and create opportunities for cross-disciplinary procedural platforms. Furthermore, the pandemic-era emphasis on single-use devices has reshaped procurement discussions by elevating infection risk and lifecycle cost alongside upfront capital considerations. Consequently, stakeholders must adapt to a landscape where product differentiation increasingly depends on ecosystem partnerships, data-enabled services, and demonstrable improvements in clinical workflows.
Projected cumulative operational and strategic consequences of United States tariffs implemented in 2025 on endoscopy device manufacturers, supply chains, and procurement dynamics
The tariff measures enacted in the United States during 2025 reshaped cost structures and sourcing strategies across the endoscopy device supply chain, prompting manufacturers and distributors to reassess production footprints and procurement channels. Immediately following tariff implementation, many suppliers evaluated nearshoring, alternative component sourcing, and supplier diversification to mitigate exposure to increased import duties. These adaptive behaviors affected lead times, inventory policies, and the relative competitiveness of products dependent on cross-border manufacturing.
In practical terms, health systems and purchasing organizations experienced upward pressure on landed costs for imported instrumentation and certain precision components, which in turn influenced purchasing cadence and contract negotiations. Meanwhile, manufacturers with established domestic assembly capabilities gained negotiating leverage and resilience, whereas smaller suppliers faced heightened margin pressure unless they passed costs through or restructured operations. Over time, these developments accelerated strategic decisions around vertical integration, supplier consolidation, and targeted product redesign to minimize tariff-sensitive inputs. Importantly, regulatory and procurement frameworks responded in kind, with payers and contracting groups increasingly scrutinizing total cost of ownership and supply continuity as part of capital procurement deliberations.
Actionable insights drawn from a granular segmentation of endoscope types, clinical applications, usage models, end users, and distribution pathways to guide product strategy
A granular segmentation view reveals distinct demand patterns that inform product development and go-to-market strategies across endoscope types, clinical applications, usage models, end users, and distribution pathways. Endoscope type differentiation among capsule, flexible, and rigid devices drives discrete design priorities: capsule systems emphasize miniaturization, battery life, and data analytics; flexible endoscopes prioritize articulation, channel compatibility, and imaging fidelity for a broad set of diagnostic and interventional procedures; rigid endoscopes continue to serve niche surgical applications where optical clarity and mechanical robustness are paramount.
Application segmentation spans arthroscopy, gastrointestinal endoscopy, laparoscopy, and urological endoscopy, each with its own procedural ecosystem. Within arthroscopy, hip, knee, and shoulder procedures present varying demands for access, optics, and instrumentation. Gastrointestinal practice areas such as colonoscopy, endoscopic ultrasound, ERCP, and gastroscopy require diverse channel configurations and therapeutic compatibility. Laparoscopy subdivides into general, gynecological, and pediatric use cases with different instrument profiles and ergonomic needs, while urological procedures like cystolithotripsy, cystoscopy, and ureteroscopy impose constraints on scope diameter, irrigation, and accessory compatibility.
Usage type presents a strategic inflection: reusable endoscopes remain attractive for high-volume, high-cost procedures where amortization makes sense, whereas single-use endoscopes respond to infection control imperatives, reprocessing labor constraints, and flexible supply needs. End user segmentation-Ambulatory Surgery Centers, hospitals, and specialty clinics-affects purchasing power, procedural mix, and the appetite for capital expenditure versus consumable-driven models. Finally, distribution channel dynamics between direct sales and distributor sales shape commercial reach, contract structures, and post-market support expectations. Taken together, these segmentation dimensions inform prioritization of R&D investment, clinical evidence generation, and tailored commercial approaches so that solutions align with distinct workflow realities and procurement behaviors.
Comparative regional intelligence across core geographies highlighting demand drivers, regulatory environments, reimbursement trends, and infrastructure readiness for endoscopy devices
Regional dynamics exert strong influence on technology adoption curves, regulatory timelines, and reimbursement mechanisms across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, purchasing behavior is driven by complex interactions among private payers, public hospitals, and ambulatory centers where capital access and value-based purchasing frameworks shape demand for devices that demonstrate procedural efficiency and patient throughput gains. Regulatory pathways in this region emphasize clinical evidence and post-market surveillance, which impacts time-to-adoption for new platform technologies.
In Europe, Middle East & Africa, heterogeneous regulatory regimes and varied healthcare infrastructure lead to differentiated adoption patterns; advanced healthcare systems in some European markets prioritize interoperability and bundled procurement, while other geographies within the region contend with constrained budgets and fragmented distribution networks. Consequently, vendors pursuing broad regional coverage must localize strategies, engage early with reimbursement bodies, and establish robust service channels. In the Asia-Pacific region, rapid hospital expansion, a growing middle class demanding minimally invasive care, and active local manufacturing hubs combine to create both opportunity and competitive intensity. Manufacturers benefit from regional partnerships, cost-optimized production, and clinical collaborations to accelerate penetration. Across all regions, stakeholders must align evidence generation, pricing strategy, and service models with local policy environments and infrastructure readiness.
Competitive intelligence on leading and emerging endoscopy device companies focusing on innovation pipelines, strategic partnerships, M&A signals, and operational resilience
Competitive dynamics among market participants center on differentiated innovation, clinical partnerships, and supply chain resilience. Leading devicemakers continue to invest in optics, miniaturization, and software-enabled capabilities to protect installed bases and create stickier revenue streams through consumables and services. At the same time, smaller and more agile entrants often focus on surgical niches, single-use concepts, or disruptive ergonomics, forcing legacy providers to accelerate product refresh cycles or pursue strategic alliances.
Strategic partnerships, co-development agreements with clinical centers, and targeted acquisitions have emerged as common playbooks to fill portfolio gaps and accelerate market access. Companies that demonstrate cross-functional excellence-combining rigorous clinical validation, field service networks, and clear total-cost considerations-tend to capture the attention of large health systems. Meanwhile, operational resilience, particularly in sourcing critical optics and electronics, remains a differentiator. Firms that diversify supplier bases, invest in redundancy, and maintain transparent supply chain communications with buyers reduce procurement friction and secure longer-term contracts. Ultimately, sustained competitive advantage will accrue to organizations that align product innovation with scalable commercial models and proactive regulatory engagement.
High-impact actionable recommendations for industry leaders to accelerate adoption, optimize supply chains, and align commercial models with evolving clinical and regulatory realities
Industry leaders should adopt a multi-dimensional strategy that balances immediate operational resiliency with long-term platform building. First, prioritize clinical evidence programs that demonstrate improvements in procedural outcomes and workflow efficiency, because payers and providers increasingly require objective data to justify adoption and reimbursement. Second, optimize supply chains by diversifying suppliers of critical components and evaluating regional assembly options to reduce exposure to tariff and logistics volatility.
Third, align commercial models with end-user economics by offering flexible pricing, outcome-based contracting where feasible, and bundled service agreements that address both capital and consumable cost centers. Fourth, accelerate digital enablement by integrating connectivity and analytics to support remote service, predictive maintenance, and enhanced clinical decision support. Fifth, pursue targeted partnerships and selective acquisitions to fill capability gaps rapidly, particularly in software, advanced imaging, and single-use consumables. Finally, invest in post-market support infrastructure and training programs to reduce adoption friction and enhance clinician confidence. Together, these actions will enable companies to respond to short-term market disruptions while building durable differentiation in an increasingly outcome-focused environment.
Transparent research methodology describing data sources, analytical frameworks, validation processes, and limitations used to synthesize the executive-level insights presented
The analysis draws on a mixed-methods research approach combining primary qualitative interviews with clinical and commercial stakeholders, synthesis of public regulatory documentation, and cross-industry benchmarking to validate thematic findings. Primary engagements included clinicians across specialties, procurement leaders, and senior operations managers who provided firsthand perspectives on procedural workflows, reprocessing practices, and procurement decision criteria. Publicly available regulatory filings and guidance documents were reviewed to contextualize market access timelines and post-market obligations.
Analytical frameworks emphasized triangulation: qualitative insights informed hypothesis generation, which was then tested against documented regulatory requirements and known commercial behaviors. Validation steps included cross-referencing supplier announcements, clinical study abstracts, and third-party logistics reports to corroborate supply chain narratives. Limitations of the methodology include reliance on available public documentation for some corporate and regulatory developments, and representativeness constraints inherent to qualitative sampling. Nevertheless, the approach prioritized high-relevance stakeholders and multiple validation layers to ensure that conclusions reflect operational realities and strategic imperatives facing manufacturers and health system purchasers.
Concise synthesis of strategic implications for stakeholders summarizing priorities, risk factors, and value levers in the evolving endoscopy device ecosystem
In closing, the endoscopy devices ecosystem is navigating a period of meaningful change where technological innovation and supply chain realities intersect with shifting clinical expectations. Stakeholders that integrate robust clinical evidence, resilient sourcing strategies, and commercially adaptable models will outperform in environments where cost containment and quality outcomes are simultaneously prioritized. Moreover, the ongoing evolution toward connected devices and data-enabled services creates new monetization pathways, but also requires disciplined regulatory engagement and clinician-centered design.
Ultimately, the imperative for manufacturers and health systems alike is to move from product-centric to outcome-centric thinking, aligning development roadmaps and procurement decisions with demonstrable clinical advantage and operational feasibility. By doing so, organizations will not only respond to immediate market pressures but also lay the groundwork for sustainable growth in a healthcare context that increasingly values safety, efficiency, and measurable patient benefit.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Rising adoption of disposable endoscopes to reduce infection transmission in healthcare settings
- 5.2. Integration of artificial intelligence and machine learning for real-time lesion detection during endoscopy
- 5.3. Development of high-definition and ultra-thin endoscopes for enhanced visualization and patient comfort
- 5.4. Growing demand for minimally invasive endoscopic treatments such as endoscopic submucosal dissection in gastrointestinal oncology
- 5.5. Expansion of tele-endoscopy services leveraging remote diagnostics and cloud-based image sharing platforms
- 5.6. Implementation of advanced 3D printing in customized endoscopy tool manufacturing to improve procedural outcomes
- 5.7. Regulatory focus on reprocessing protocols driving innovation in sterile single-use endoscopic accessories
- 5.8. Emergence of robotic-assisted endoscopic systems to enhance precision in complex gastrointestinal procedures
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Endoscopy Devices Market, by Endoscope Type
- 8.1. Capsule Endoscopes
- 8.2. Flexible Endoscopes
- 8.3. Rigid Endoscopes
- 9. Endoscopy Devices Market, by Application
- 9.1. Arthroscopy
- 9.1.1. Hip Arthroscopy
- 9.1.2. Knee Arthroscopy
- 9.1.3. Shoulder Arthroscopy
- 9.2. Gastrointestinal Endoscopy
- 9.2.1. Colonoscopy
- 9.2.2. Endoscopic Ultrasound
- 9.2.3. ERCP
- 9.2.4. Gastroscopy
- 9.3. Laparoscopy
- 9.3.1. General Laparoscopy
- 9.3.2. Gynecological Laparoscopy
- 9.3.3. Pediatric Laparoscopy
- 9.4. Urological Endoscopy
- 9.4.1. Cystolithotripsy
- 9.4.2. Cystoscopy
- 9.4.3. Ureteroscopy
- 10. Endoscopy Devices Market, by Usage Type
- 10.1. Reusable Endoscopes
- 10.2. Single Use Endoscopes
- 11. Endoscopy Devices Market, by End User
- 11.1. Ambulatory Surgery Centers
- 11.2. Hospitals
- 11.3. Specialty Clinics
- 12. Endoscopy Devices Market, by Distribution Channel
- 12.1. Direct Sales
- 12.2. Distributor Sales
- 13. Endoscopy Devices Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Endoscopy Devices Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Endoscopy Devices Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Olympus Corporation
- 16.3.2. Medtronic plc
- 16.3.3. Stryker Corporation
- 16.3.4. Johnson & Johnson
- 16.3.5. Boston Scientific Corporation
- 16.3.6. FUJIFILM Holdings Corporation
- 16.3.7. HOYA Corporation
- 16.3.8. Karl Storz SE & Co. KG
- 16.3.9. Smith & Nephew plc
- 16.3.10. Conmed Corporation
- 16.3.11. Ambu A/S
- 16.3.12. Asensus Surgical, Inc.
- 16.3.13. Auris Health, Inc.
- 16.3.14. avateramedical GmbH
- 16.3.15. Brainlab AG
- 16.3.16. CMR Surgical Ltd.
- 16.3.17. Cook Group Incorporated
- 16.3.18. Endocontrol SA by Canady Life Sciences, Inc.
- 16.3.19. EndoMaster Pte Ltd
- 16.3.20. Endotics
- 16.3.21. Globus Medical, Inc.
- 16.3.22. Intuitive Surgical, Inc.
- 16.3.23. MicroPort Scientific Corporation
- 16.3.24. Otsuka Holdings Co., Ltd.
- 16.3.25. Renishaw PLC
- 16.3.26. Virtuoso Surgical, Inc.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
